Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 9
1965 75
1966 132
1967 159
1968 166
1969 130
1970 156
1971 145
1972 123
1973 142
1974 136
1975 154
1976 141
1977 154
1978 152
1979 133
1980 123
1981 146
1982 141
1983 140
1984 148
1985 161
1986 165
1987 150
1988 150
1989 225
1990 200
1991 214
1992 218
1993 233
1994 290
1995 285
1996 338
1997 292
1998 331
1999 377
2000 378
2001 394
2002 514
2003 502
2004 591
2005 572
2006 647
2007 706
2008 762
2009 624
2010 700
2011 695
2012 736
2013 761
2014 668
2015 675
2016 673
2017 652
2018 639
2019 605
2020 759
2021 893
2022 819
2023 730
2024 310

Text availability

Article attribute

Article type

Publication date

Search Results

20,532 results

Results by year

Filters applied: . Clear all
Page 1
Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors.
Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Leucht S, et al. Am J Psychiatry. 2017 Oct 1;174(10):927-942. doi: 10.1176/appi.ajp.2017.16121358. Epub 2017 May 25. Am J Psychiatry. 2017. PMID: 28541090 Review.
Potential drug targets and treatment of schizophrenia.
Kumar A, Yadav M, Parle M, Dhingra S, Dhull DK. Kumar A, et al. Inflammopharmacology. 2017 Jun;25(3):277-292. doi: 10.1007/s10787-017-0340-5. Epub 2017 Mar 28. Inflammopharmacology. 2017. PMID: 28353125 Review.
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Krystal JH, et al. Lancet. 2022 Dec 17;400(10369):2210-2220. doi: 10.1016/S0140-6736(22)01990-0. Lancet. 2022. PMID: 36528376 Clinical Trial.
Schizophrenia.
Mosqueda RA, Davidson JE. Mosqueda RA, et al. N Engl J Med. 1994 Jul 28;331(4):275-6. doi: 10.1056/NEJM199407283310415. N Engl J Med. 1994. PMID: 7517015 No abstract available.
20,532 results
You have reached the last available page of results. Please see the User Guide for more information.